Listen: Pharma’s lobbying dollars, Alnylam’s future, and diversity in Covid-19 studies
Is pharma scared of Kamala Harris? Are there second acts in biotech? And why aren’t Covid-19 clinical trials enrolling diverse participants?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Lev Facher joins us to talk about Sen. Kamala Harris’ health care record and how the drug industry is spending its lobbying dollars in 2020. Then, soon-to-be-former Alynlam Pharmaceuticals President Barry Greene calls in to look back on his career at the ascendant company and at what comes next. Finally, oncologist Hala Borno joins us to discuss the lack of diversity in Covid-19 trials and why science has to do better.
